Busca avançada
Ano de início
Entree
(Referência obtida automaticamente do Web of Science, por meio da informação sobre o financiamento pela FAPESP e o número do processo correspondente, incluída na publicação pelos autores.)

Immunogenicity and safety of two doses of a non-adjuvanted influenza A H1N1/2009 vaccine in young autoimmune rheumatic diseases patients

Texto completo
Autor(es):
Aikawa, N. E. [1, 2] ; Trudes, G. [2] ; Campos, L. M. A. [2] ; Pereira, R. M. R. [1] ; Moraes, J. C. B. [1] ; Ribeiro, A. C. [1] ; Miraglia, J. [3] ; Timenetsky, M. do Carmo S. [4] ; Bonfa, E. [1] ; Silva, C. A. [2, 1]
Número total de Autores: 10
Afiliação do(s) autor(es):
[1] Univ Sao Paulo, Div Rheumatol, BR-05508 Sao Paulo - Brazil
[2] Univ Sao Paulo, Pediat Rheumatol Unit, BR-05508 Sao Paulo - Brazil
[3] Univ Sao Paulo, Inst Butantan, BR-05508 Sao Paulo - Brazil
[4] Univ Sao Paulo, Inst Adolfo Lutz, BR-05508 Sao Paulo - Brazil
Número total de Afiliações: 4
Tipo de documento: Artigo Científico
Fonte: Lupus; v. 22, n. 13, p. 1394-1398, NOV 2013.
Citações Web of Science: 7
Resumo

Objectives The aim of this study was to evaluate the immunogenicity and safety of the influenza A H1N1/2009 vaccine in children under 9 years old with autoimmune rheumatic diseases (ARD). Methods Thirty-eight ARD patients and 11 healthy children received two doses of non-adjuvanted influenza A/California/7/2009 (H1N1) virus-like vaccine. Subjects were evaluated before and 21 days after vaccination. Seroprotection (SP) and seroconversion (SC) rates, geometric mean titers (GMT) and factor increases (FI) in GMT were calculated. Results Mean ages were comparable between patients and controls. Pre-vaccination SP and GMT were similar in patients and controls (p>0.05). Three weeks after immunization, SP (81.6% vs. 81.8%, p=1.0), SC (81.6% vs. 90.9%, p=0.66), GMT (151.5 vs. 282.1, p=0.26) and the FI in GMT (16.7 vs. 36.3, p=0.23) were similar in patients and controls, with both groups achieving an adequate response, according to the European Medicines Agency and Food and Drug Administration standards. Analysis of the possible factors influencing SC showed no difference in demographic data, leukocyte/lymphocyte counts or immunosuppressant use between seroconverted and non-seroconverted patients (p>0.05). The vaccine demonstrated a satisfactory safety profile in this population. Conclusions Two doses of influenza A H1N1/2009 vaccination induced an effective antibody response and caused adverse events in rare instances, suggesting this vaccine is appropriate and can be recommended for this age group. (AU)

Processo FAPESP: 10/10749-0 - Vacina anti-influenza H1N1/2009 em pacientes com doenças reumáticas autoimunes
Beneficiário:Eloisa Silva Dutra de Oliveira Bonfá
Linha de fomento: Auxílio à Pesquisa - Regular
Processo FAPESP: 09/51897-5 - Terapia anti-TNF em doenças auto-imunes reumatológicas: abordagem de aspectos peculiares
Beneficiário:Eloisa Silva Dutra de Oliveira Bonfá
Linha de fomento: Auxílio à Pesquisa - Temático